These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 22784140)

  • 1. Effect of abuse-deterrent formulation of OxyContin.
    Cicero TJ; Ellis MS; Surratt HL
    N Engl J Med; 2012 Jul; 367(2):187-9. PubMed ID: 22784140
    [No Abstract]   [Full Text] [Related]  

  • 2. Abuse-Deterrent Formulations and the Prescription Opioid Abuse Epidemic in the United States: Lessons Learned From OxyContin.
    Cicero TJ; Ellis MS
    JAMA Psychiatry; 2015 May; 72(5):424-30. PubMed ID: 25760692
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The introduction of a potentially abuse deterrent oxycodone formulation: Early findings from the Australian National Opioid Medications Abuse Deterrence (NOMAD) study.
    Degenhardt L; Bruno R; Ali R; Lintzeris N; Farrell M; Larance B
    Drug Alcohol Depend; 2015 Jun; 151():56-67. PubMed ID: 25910850
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluating the potential impact of a reformulated version of oxycodone upon tampering, non-adherence and diversion of opioids: the National Opioid Medications Abuse Deterrence (NOMAD) study protocol.
    Degenhardt L; Larance B; Bruno R; Lintzeris N; Ali R; Farrell M
    Addiction; 2015 Feb; 110(2):226-37. PubMed ID: 25358480
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sustained reduction of diversion and abuse after introduction of an abuse deterrent formulation of extended release oxycodone.
    Severtson SG; Ellis MS; Kurtz SP; Rosenblum A; Cicero TJ; Parrino MW; Gilbert MK; Buttram ME; Dasgupta N; BucherBartelson B; Green JL; Dart RC
    Drug Alcohol Depend; 2016 Nov; 168():219-229. PubMed ID: 27716575
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of abuse-deterrent OxyContin on prescription opioid utilization.
    Hwang CS; Chang HY; Alexander GC
    Pharmacoepidemiol Drug Saf; 2015 Feb; 24(2):197-204. PubMed ID: 25393216
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The impact of a reformulation of extended-release oxycodone designed to deter abuse in a sample of prescription opioid abusers.
    Havens JR; Leukefeld CG; DeVeaugh-Geiss AM; Coplan P; Chilcoat HD
    Drug Alcohol Depend; 2014 Jun; 139():9-17. PubMed ID: 24721614
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Attractiveness of reformulated OxyContin(R) tablets: assessing comparative preferences and tampering potential.
    Sellers EM; Perrino PJ; Colucci SV; Harris SC
    J Psychopharmacol; 2013 Sep; 27(9):808-16. PubMed ID: 23784739
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Abuse-deterrent properties of REMOXY® ER, a high-viscosity extended-release oxycodone formulation.
    Kucera SA; Zamloot MS; Crowley MM; Burns LH; Friedmann N; Barbier R
    J Opioid Manag; 2018; 14(6):429-436. PubMed ID: 30629279
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estimating attractiveness for abuse of a not-yet-marketed "abuse-deterrent" prescription opioid formulation.
    Butler SF; Black R; Grimes Serrano JM; Folensbee L; Chang A; Katz N
    Pain Med; 2010 Jan; 11(1):81-91. PubMed ID: 20002324
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The release of abuse-deterrent OxyContin and adolescent heroin use.
    DiNardi M
    Drug Alcohol Depend; 2021 Dec; 229(Pt B):109114. PubMed ID: 34638038
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Probable relationship between opioid abuse and heroin use.
    Siegal HA; Carlson RG; Kenne DR; Swora MG
    Am Fam Physician; 2003 Mar; 67(5):942, 945. PubMed ID: 12643356
    [No Abstract]   [Full Text] [Related]  

  • 13. Societal economic benefits associated with an extended-release opioid with abuse-deterrent technology in the United States.
    Kirson NY; Shei A; White AG; Birnbaum HG; Ben-Joseph R; Rossiter LF; Michna E
    Pain Med; 2014 Sep; 15(9):1450-4. PubMed ID: 25041231
    [No Abstract]   [Full Text] [Related]  

  • 14. Development and impact of prescription opioid abuse deterrent formulation technologies.
    Alexander L; Mannion RO; Weingarten B; Fanelli RJ; Stiles GL
    Drug Alcohol Depend; 2014 May; 138():1-6. PubMed ID: 24613631
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Abuse rates and routes of administration of reformulated extended-release oxycodone: initial findings from a sentinel surveillance sample of individuals assessed for substance abuse treatment.
    Butler SF; Cassidy TA; Chilcoat H; Black RA; Landau C; Budman SH; Coplan PM
    J Pain; 2013 Apr; 14(4):351-8. PubMed ID: 23127293
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A profile of OxyContin addiction.
    Hays LR
    J Addict Dis; 2004; 23(4):1-9. PubMed ID: 15339710
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 'Opioid drought', Canadian-style? Potential implications of the 'natural experiment' of delisting oxycontin in Canada.
    Fischer B; Keates A
    Int J Drug Policy; 2012 Nov; 23(6):495-7. PubMed ID: 22940141
    [No Abstract]   [Full Text] [Related]  

  • 18. An iterative model for in vitro laboratory assessment of tamper deterrent formulations.
    Cone EJ; Giordano J; Weingarten B
    Drug Alcohol Depend; 2013 Jul; 131(1-2):100-5. PubMed ID: 23332441
    [TBL] [Abstract][Full Text] [Related]  

  • 19. OxyContin Use and Abuse.
    Hancock CM; Burrow MA
    Clin J Oncol Nurs; 2002; 6(2):109-10. PubMed ID: 11889673
    [No Abstract]   [Full Text] [Related]  

  • 20. The development of a comprehensive risk-management program for prescription opioid analgesics: researched abuse, diversion and addiction-related surveillance (RADARS).
    Cicero TJ; Dart RC; Inciardi JA; Woody GE; Schnoll S; Muñoz A
    Pain Med; 2007 Mar; 8(2):157-70. PubMed ID: 17305687
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.